Benitec Biopharma Inc BNTC 深 沪

Benitec Biopharma Q3 EPS $(0.24) Beats $(0.27) Estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 36.84 percent increase over losses of $(0.38) per share from

05-14 20:41

美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级

今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元

05-13 11:46

Evercore ISI Group Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $25

Evercore ISI Group analyst Cory Kasimov initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $25.

05-12 23:24

Benitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual Meeting

04-28 11:00

美股大行评级 | 潜在涨幅148%！瑞银、小摩等8家大行首予SOLV Energy买入评级目标价42美元；甲骨文绩前遭德银等下调目标价；京东遭巴克莱下调目标价

今日重点评级关注：Evercore ISI集团：维持Caribou Biosciences"跑赢大市"评级，目标价从11美元升至13美元；富国银行：上调uniQure评级至"超配"，目标价从15美元升至60美元

03-10 15:05

Benitec Biopharma Announces Positive Interim Phase 1b/2a Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 Treatment at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference

Benitec Biopharma announced promising interim results from the BB-301 Phase 1b/2a study for Oculopharyngeal Muscular Dystrophy (OPMD) patients with moderate dysphagia. Both low and high doses of BB-301 showed significant improvements in throat closure, emptying, and dysphagic symptoms. High-dose BB-301 demonstrated particularly robust responses, with a 68% reduction in dysphagic symptom burden and improved outcomes across all assessments. Low-dos...

03-09 11:00

Benitec Biopharma BB-301 Phase 1b/2a Late-Breaking Abstract Accepted At 2026 Muscular Dystrophy Association Clinical And Scientific Conference

-Interim clinical study results for the BB-301 Phase 1b/2a Treatment Study including 12-month follow-up results for the first four Cohort 1 completers, 24-month clinical study results for the first Cohort 1 Patient, and

02-23 20:06

Benitec Biopharma Announces Acceptance of Late- Breaking Abstract for the BB-301 Phase 1b/2a Clinical Treatment Study at the Muscular Dystrophy Association Clinical & Scientific Conference

Benitec Biopharma Inc. announced that interim results from its Phase 1b/2a clinical trial of BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD) will be presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference on March 9. The presentation will include 12-month follow-up data for the first four Cohort 1 completers, 24-month results for the first Cohort 1 patient, and interim data for the first Cohort 2 patient. BB-301...

02-23 12:00

Benitec Biopharma Q2 EPS $(0.26) Misses $(0.22) Estimate

Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.22) by 16.59 percent. This is unchanged from the same period last year.

02-12 22:07

Benitec Biopharma Q2 net loss widens

Benitec Biopharma Q2 net loss widens Overview Gene therapy firm's Q2 net loss widened to $11.8 mln Company's R&D expenses in Q2 were $5.8 mln, consistent with last year Company plans FDA meeting mid-2026 for BB-301 pivotal study design Outlook Company plans FDA meeting to finalize BB-301 pivotal stu

02-12 21:37